NOVO NORDISK TO SUBMIT BLUNT TRAUMA DRUG APPLICATION

Denmark-based drug producer Novo Nordisk has announced that it has finished compiling a European Medicines Agency dossier on a new blunt trauma treatment. The company states that the prospective medicine, known as NovoSeven, is a coagulation factor VIIa recombinant in blunt trauma. US trials on human subjects for this purpose are expected are to begin in the second quarter. Further, the company is also seeking US FDA approval for the compound as a treatment for intracerebral hemorrhage, with trials in the US and Europe due to begin by mid-2005, surveying some 450 patients.

Meanwhile, Novo Nordisk has also appointed its former Canada president, Claus Eilersen, as president of the company. Eilersen replaces Roger Moore, who is to become company chairman, as well as remaining senior vice-president for Japan and Oceania.